NCT06858527 Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
| NCT ID | NCT06858527 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Attention Deficit Hyperactivity Disorder (ADHD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 132 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2029-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 132 participants in total. It began in 2025-04-01 with a primary completion date of 2029-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences. However, and despite the international consensus recommending integrated treatment for this comorbidity, few studies tested the efficacy of specific psychotherapeutic treatment for this comorbidity. The aim of this study is to test the efficacy of a specific group Cognitive and Behavioral Therapy (CBT) for the treatment of adults with this comorbidity. This is a longitudinal, randomized controlled intervention study utilizing a crossover design between the intervention and treatment-as-usual (TAU) waitlist condition, aimed at testing the effectiveness of an integrated psychotherapeutic group treatment for adults with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs).
Eligibility Criteria
Inclusion Criteria: * Age 18 or older ; * Suffer from at least one moderate to severe SUD regarding the DSM-5 (tobacco excluded) ; * Being currently treated for a SUD by a physician of a psychologist ; * Being diagnosed with an ADHD according to the DIVA 2.0 of DIVA-5 ; * Being affiliated to a health insurance ; * Understanding and being able to express himselves in French * Signed consent Exclusion Criteria: * Age under 18; * Pregnant or breastfeeding women; * Not having sign the consent form; * Major difficulties in understanding and/or expressing themselves in french; * Severe cognitive impairment; * Acute medical condition making assessment impossible and/or contraindicating participation in group intervention; * Substance use disorder in a protected environment, currentlu or in the last 15 days, or expected during the study; * No substance use disorder other than tobacco use disorder; * Persons under guardianship; * Participant deprived of liberty or under penal care orders; * Participation in another group psychotherapeutic intervention throughout the duration of the intervention
Contact & Investigator
Norman Therribout, PhD
PRINCIPAL INVESTIGATOR
Paris-Nanterre University, UR-4430 CLIPSYD ; Paris-Cité University, UMR-S-1144 INSERM; Fernand-Widal Hospital AP-HP
Frequently Asked Questions
Who can join the NCT06858527 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Attention Deficit Hyperactivity Disorder (ADHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06858527 currently recruiting?
Yes, NCT06858527 is actively recruiting participants. Contact the research team at norman.therribout@aphp.fr for enrollment information.
Where is the NCT06858527 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06858527 clinical trial?
NCT06858527 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Norman Therribout, PhD at Paris-Nanterre University, UR-4430 CLIPSYD ; Paris-Cité University, UMR-S-1144 INSERM; Fernand-Widal Hospital AP-HP. The trial plans to enroll 132 participants.